S100A9 and cardiomyopathy: Conversely, studies have revealed that the inhibition of S100A9 holds pivotal therapeutic significance in a plethora of CVD, encompassing atherosclerosis, MI, PAH, PAD, cardiomyopathy, and myocarditis.